

HE Dr. Kosmosbek Cholponbaev
The Minister of Health
Ministry of Health
Moskovskaya Str. 148
720040 Bishkek
The Republic of Kyrgyzstan

19 March 2019

Decision Letter: Request for Rotavirus vaccine support

Your Excellency,

I am writing in relation to Kyrgyzstan's application for New Vaccines Support (NVS) for Rotavirus Programme, which was submitted to the Gavi Secretariat in September 2017.

In November 2017, the Independent Review Committee (IRC) reviewed your request and recommended approval subject to clarifications. Based on the country's response to clarifications, the IRC recommended **approval** of the Rotavirus vaccine support to the country, subject to conditions and requirements as described in Annex A to this letter.

In February 2019, Gavi's Secretariat took note of Kyrgyzstan's request to switch vaccine preference from *Rotarix, RV1, in plastic tubes* to *Rotasiil, RV5, 2 doses per vial, lyophilised*, due to the current supply disruption of Rotarix.

For any question or requests for additional information, please feel free to contact the Senior Country Manager, Ms Jamilya Sherova at jsherova@gavi.org.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative
UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

**Decision Letter -
The Republic of Kyrgyzstan - Support for Rotavirus Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Kyrgyzstan				
2. Grant number: 1921-KGZ-13f-X Vaccine Introduction Grant number: 19-KGZ-08b-Y				
3. Date of Decision Letter: 19/03/2019				
4. Date of the Partnership Framework Agreement: 16/05/2014				
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine				
6. Vaccine type: Rotavirus				
7. Requested product presentation and formulation of vaccine: Rotasiil, RV5, 2 doses per vial, lyophilised				
8. Programme duration¹: 2019 - 2021				
9. Programme Budget (indicative): (subject to the terms of the partnership framework agreement)				
	2019	2020	2021	Total ²
Programme Budget (US\$)	US\$432,500	US\$553,500	US\$682,000	US\$1,668,000
10. Vaccine introduction grant (in US\$): US\$ 116,257, approved for 2019 as implementation year, payable up to six months before vaccine introduction.				
11. Product switch grant: Not applicable				
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³				
Type of supplies to be purchased with Gavi funds in each year	2019	2020		
Number of Rotavirus vaccines doses	278,800	357,000		
Annual Amounts (US\$)	US\$432,500	US\$553,500		
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement: Not applicable				
15. Co-financing obligations: Reference code: 1921-KGZ-13f-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	2019	2020	2021	
Number of vaccine doses	63,500	96,700	142,800	
Value of vaccine doses (US\$)	US\$98,314	US\$149,860	US\$221,295	
Total co-financing payments (US\$) (including freight)	US\$98,500	US\$150,000	US\$221,500	
16. Operational support for campaigns: Not applicable				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

17. Additional reporting requirements: Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
19th of March, 2019